Related Experiment Video
Updated: Nov 19, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Pre- and Post-Transcriptional Regulation of cFLIP for Effective Cancer Therapy Using pH-Ultrasensitive Nanoparticles
Cao Dai Phung1, Tuan Hiep Tran2,3, Ju-Yeon Choi1
1College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Abstract:
Cellular FLIP (cFLIP) is a crucial player of apoptosis-regulated pathways that is frequently overexpressed in solid cancers. To inhibit c-FLIP, pre- and post-transcriptionally, a multifunctional nanoparticle (NP) was created to deliver cFLIP-specific small interfering RNA (siRNA) into cancer cells. Specifically, Vorinostat (Vor)-loaded mesoporous silica nanoparticles (MSN) were conjugated with polyethylenimine-biotin (PB), followed by electrostatically binding with cFLIP siRNA (Vor/siR@MSN-PB). To stabilize and prolong the circulation time of nanoparticles, a bialdehyde-modified poly(ethylene glycol) (PEG) was cross-linked onto the polyethylenimine (PEI) backbone via the formation of the imine linkage (Schiff base) (Vor/siR@MSN-PB-PEG). The Schiff base is highly stable at physiological pH 7.4 but labile under slightly acidic pH conditions. In the acidic tumor microenvironment (TME), the PEG outer layer could be rapidly cleaved, resulting in the switching of the nanoparticle surface charge to positive, which specifically enhances internalization of the NPs to the biotin-positive tumor cells. Our results demonstrated the successful preparation of Vor/siR@MSN-PB-PEG NPs, in which the siRNA was effectively protected in serum and regulated the expression of cFlip, post-transcriptionally. The presence of the PEG layer resulted in high tumor accumulation and high efficacy in tumor inhibition, which was a result of the efficient cFLIP suppression. Furthermore, in the low-dose regimen of Vorinostat-the pre-transcriptional cFLIP suppressor, treatment with Vor/siR@MSN-PB-PEG NPs was found to be safe with the treated mice, indicating a promising combination regimen for cancer therapy.
Insights
This study developed a novel nanoparticle to deliver cFLIP-specific siRNA and Vorinostat, effectively inhibiting cancer cell growth. The nanoparticle showed promising safety and efficacy in preclinical models for cancer therapy.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Biology
Background:
- Cellular FLIP (cFLIP) is overexpressed in solid cancers, driving apoptosis resistance.
- Targeting cFLIP offers a therapeutic strategy for cancer treatment.
- Developing effective delivery systems for cFLIP inhibitors is crucial.
Purpose of the Study:
- To create a multifunctional nanoparticle for co-delivery of cFLIP-specific siRNA and Vorinostat.
- To achieve pre- and post-transcriptional inhibition of cFLIP in cancer cells.
- To enhance nanoparticle tumor targeting and cellular uptake in the acidic tumor microenvironment.
Main Methods:
- Fabrication of mesoporous silica nanoparticles (MSN) loaded with Vorinostat (Vor).
- Conjugation with polyethylenimine-biotin (PB) and electrostatic binding of cFLIP siRNA (siR).
- PEGylation via Schiff base linkage for pH-sensitive deprotection and charge switching.
Main Results:
- Successful synthesis of Vor/siR@MSN-PB-PEG nanoparticles with serum-stable siRNA.
- Demonstrated post-transcriptional cFLIP downregulation by siRNA.
- Achieved enhanced tumor accumulation and significant tumor inhibition due to targeted delivery and cFLIP suppression.
Conclusions:
- The developed nanoparticle system effectively co-delivers siRNA and Vorinostat for synergistic cancer therapy.
- pH-sensitive PEGylation enables targeted delivery and enhanced cellular internalization.
- The combination regimen shows promising safety and efficacy for preclinical cancer treatment.
More Related Videos
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
08:14Detection of Intracellular Gene Expression in Live Cells of Murine, Human and Porcine Origin Using Fluorescence-labeled Nanoparticles
Published on: November 13, 2015